Vtama (tapinarof), the first new topical psoriasis drug to get the agency’s okay in 25 years, is set to launch in early June. On May 24, the U.S. Food and Drug Administration (FDA) approved Vtama ...

In a retrospective cohort study published in JAAD, the study authors explored the relationship between psoriasis flares and corticosteroid use. Of the psoriasis patients, 56% experienced a psoriasis ...

Despite recent significant advances in systemic therapies for psoriasis, topical treatment retains a prominent role for many patients. The American Academy of Dermatology/National Psoriasis Foundation ...

Researchers suggest a short-term application of topical corticosteroids and maintenance with a less potent agent for patients with intertriginous psoriasis (IP), according to a study published in the ...

Please provide your email address to receive an email when new articles are posted on . The rate of psoriasis flares did not increase during or immediately after systemic corticosteroid treatment, ...

Psoriasis: When the ‘usual suspect’ therapy works Topical corticosteroids and ultraviolet therapies are still proving to be strong competitors in psoriasis treatment. Ms. S, aged 37 years, presented ...

Challenges in choosing between corticosteroids and noncorticosteroids for pediatric dermatologic conditions include balancing efficacy, safety, compliance, and long-term management while considering ...

RALEIGH, N.C., Sept. 21, 2021 /PRNewswire/ -- Mayne Pharma is pleased to announce that the U.S. Food and Drug Administration (FDA) has approved LEXETTE® (halobetasol propionate) foam, 0.05% for use in ...

Genital psoriasis can cause red or purple lesions that may be itchy and painful. Treatments include topical corticosteroids ...

Learn what collagen is, why it may or may not have benefits for psoriasis, according to experts, and what the research has found so far.

Yousuf Mohammed receives funding from U.S FDA grants. This article reflects the views of the author and should not be construed to represent views or policies. Khadeejeh AL-Smadi does not work for, ...